Jihua Yang1, Shunchang Jiao2, Jingbo Kang1, Rong Li3, Guanzhong Zhang4. 1. Center of Tumor Therapy, Navy General Hospital Beijing 100048, China. 2. Department of Medical Oncology, Chinese People's Liberation Army General Hospital Beijing 100853, China. 3. Second Military Medical University Shanghai 200433, China. 4. Department of Medical Oncology, General Hospital of Shenyang Military Command Shenyang, Liaoning Province, China.
Abstract
BACKGROUND: NY-ESO-1 antibody is one of the cancer-related antibodies. The purpose of this study was to investigate the diagnostic role of the NY-ESO-1 humoral immune response in small cell lung cancer (SCLC). METHODS: We recombined the recombinant protein of NY-ESO-1 antibody and NSE, analyzed them by Enzyme-linked immunosorbent assay, and then established the Receiver Operating Characteristic (ROC) curve to estimate the diagnostic value of NY-ESO-1 antibody, NSE and their combinations. RESULTS: According to detection, the positive rate of NY-ESO-1 humoral immune response (26.3%), NSE (43.8%) and their combinations (10.5%) were all lower than the negative rate which indicated that the NY-ESO-1 antibody might be down-regulated in SCLC. And the positive rate wasn't related to clinicopathologic characteristics. The ROC curve demonstrated that with a 37.17% sensitivity and a 91.7% specificity along with a AUC of 0.619 for NY-ESO-1ab as well as with a 48.3% sensitivity and a 90.87% specificity along with a AUC value of 0.773 for NSE, their diagnostic value were both high. Besides, the diagnostic value of their combinations was also good for a AUC of 0.83 and a 69.12% sensitivity and a 91.8% specificity. There were significant difference of diagnostic value among three types above (NY-ESO-1 vs. NSE, P < 0.01; The Combinations vs. NY-ESO-1, P < 0.0001; and the Combinations vs. NSE, P < 0.04). CONCLUSION: In conclusion, NY-ESO-1ab, NSE and their combinations all were important diagnostic markers for SCLC. Moreover, the diagnostic value of their combinations was higher than any single of them. And NY-ESO-1 humoral immune to NSE might be a potential diagnostic indicator in SCLC.
BACKGROUND:NY-ESO-1 antibody is one of the cancer-related antibodies. The purpose of this study was to investigate the diagnostic role of the NY-ESO-1 humoral immune response in small cell lung cancer (SCLC). METHODS: We recombined the recombinant protein of NY-ESO-1 antibody and NSE, analyzed them by Enzyme-linked immunosorbent assay, and then established the Receiver Operating Characteristic (ROC) curve to estimate the diagnostic value of NY-ESO-1 antibody, NSE and their combinations. RESULTS: According to detection, the positive rate of NY-ESO-1 humoral immune response (26.3%), NSE (43.8%) and their combinations (10.5%) were all lower than the negative rate which indicated that the NY-ESO-1 antibody might be down-regulated in SCLC. And the positive rate wasn't related to clinicopathologic characteristics. The ROC curve demonstrated that with a 37.17% sensitivity and a 91.7% specificity along with a AUC of 0.619 for NY-ESO-1ab as well as with a 48.3% sensitivity and a 90.87% specificity along with a AUC value of 0.773 for NSE, their diagnostic value were both high. Besides, the diagnostic value of their combinations was also good for a AUC of 0.83 and a 69.12% sensitivity and a 91.8% specificity. There were significant difference of diagnostic value among three types above (NY-ESO-1 vs. NSE, P < 0.01; The Combinations vs. NY-ESO-1, P < 0.0001; and the Combinations vs. NSE, P < 0.04). CONCLUSION: In conclusion, NY-ESO-1ab, NSE and their combinations all were important diagnostic markers for SCLC. Moreover, the diagnostic value of their combinations was higher than any single of them. And NY-ESO-1 humoral immune to NSE might be a potential diagnostic indicator in SCLC.
Authors: R M Xavier; Y Yamauchi; M Nakamura; Y Tanigawa; H Ishikura; T Tsunematsu; S Kobayashi Journal: Mech Ageing Dev Date: 1995-03-01 Impact factor: 5.432
Authors: Li Zhong; Sarah P Coe; Arnold J Stromberg; Nada H Khattar; James R Jett; Edward A Hirschowitz Journal: J Thorac Oncol Date: 2006-07 Impact factor: 15.609
Authors: Malcolm V Brock; Craig M Hooker; James E Syphard; William Westra; Li Xu; Anthony J Alberg; David Mason; Stephen B Baylin; James G Herman; Rex C Yung; Julie Brahmer; Charles M Rudin; David S Ettinger; Stephen C Yang Journal: J Thorac Cardiovasc Surg Date: 2005-01 Impact factor: 5.209
Authors: M N Manoussakis; A G Tzioufas; M P Silis; P J Pange; J Goudevenos; H M Moutsopoulos Journal: Clin Exp Immunol Date: 1987-09 Impact factor: 4.330
Authors: P Boyle; C J Chapman; S Holdenrieder; A Murray; C Robertson; W C Wood; P Maddison; G Healey; G H Fairley; A C Barnes; J F R Robertson Journal: Ann Oncol Date: 2010-07-30 Impact factor: 32.976
Authors: E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old Journal: J Exp Med Date: 1998-04-20 Impact factor: 14.307